ID

15503

Descrição

Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT02252887

Link

https://clinicaltrials.gov/show/NCT02252887

Palavras-chave

Versões (1)
  1. 01/06/2016 01/06/2016 -
Transferido a

1 de junho de 2016

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Metastatic HER2-Positive Breast Cancer NCT02252887

Inglês

Eligibility Metastatic HER2-Positive Breast Cancer NCT02252887

1 Formulários  
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
age ≥ to 18
Descrição

Age

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0001779
stage iv her2 (+) breast cancer
Descrição

HER2-positive carcinoma of breast | Tumor Stage Classification

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1960398
UMLS CUI [2]
C0178759
histologically documented her2 (+) breast cancer as defined as ihc 3+ or fish amplification of ≥ 2.0 of primary or metastatic site; results from the local lab are acceptable.
Descrição

HER2-positive carcinoma of breast | Immunohistochemistry | Fluorescent in Situ Hybridization | Primary tumor site | Site, metastatic cancer

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1960398
UMLS CUI [2]
C0021044
UMLS CUI [3]
C0162789
UMLS CUI [4]
C0475447
UMLS CUI [5]
C0280457
lecog performance status 0 -1
Descrição

ECOG performance status

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1520224
prior treatment with trastuzumab + pertuzumab (hp)-based therapy or pertuzumab-based in the neoadjuvantadjuvant, unresectable, locally advanced, or metastatic setting.
Descrição

Prior Therapy | trastuzumab | pertuzumab | Neoadjuvant Therapy | unresectable | Locally advanced breast cancer | metastatic

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1514463
UMLS CUI [2]
C0728747
UMLS CUI [3]
C1328025
UMLS CUI [4]
C0600558
UMLS CUI [5]
C1519810
UMLS CUI [6]
C3495949
UMLS CUI [7]
C1522484
≤ 3 prior chemotherapies in the metastatic setting. prior anthracycline, taxane, gemcitabine, and anti-her2 agents (i.e. trastuzumab, pertuzumab, lapatinib, neratinib, tdm-1, etc.) are allowed. if patients received prior gemcitabine, it could not have been combined with pertuzumab. patients should have progression of disease on current therapy.
Descrição

Prior Chemotherapy | metastatic | Anthracyclines | taxane | gemcitabine | trastuzumab | pertuzumab | lapatinib | neratinib | T-DM1 | Disease Progression

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1514457
UMLS CUI [2]
C1522484
UMLS CUI [3]
C0282564
UMLS CUI [4]
C0215136
UMLS CUI [5]
C0045093
UMLS CUI [6]
C0728747
UMLS CUI [7]
C1328025
UMLS CUI [8]
C1506770
UMLS CUI [9]
C2713008
UMLS CUI [10]
C2935436
UMLS CUI [11]
C0242656
measurable or non-measurable disease.
Descrição

Measurable Disease

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1513041
lvef ≥ 50%
Descrição

LVEF

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0428772
hematologic parameters: white blood cell (wbc) count of ≥ 3000/ul, absolute neutrophil count (anc) ≥ 1000/ul, platelets ≥ 100,000/ul, hemoglobin ≥10.0 g/dl
Descrição

Parameters Hematologic | White Blood Cell Count procedure | Absolute neutrophil count | Platelet Count measurement | Hemoglobin

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0449381
UMLS CUI [1,2]
C0205488
UMLS CUI [2]
C0023508
UMLS CUI [3]
C0948762
UMLS CUI [4]
C0032181
UMLS CUI [5]
C0019046
non-hematologic parameters: bilirubin ≤ 1.5 mg/dl, ast/alt≤ 2.5 x upper limit of normal (uln), alkaline phosphatase ≤ 5 x uln.
Descrição

Parameters | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0449381
UMLS CUI [2]
C1278039
UMLS CUI [3]
C0201899
UMLS CUI [4]
C0201836
UMLS CUI [5]
C0201850
creatinine ≤ 1.5 mg/dl
Descrição

Creatinine measurement, serum

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0201976
patients with "treated and stable" brain lesions of a duration of ≥ 2 months may be enrolled.
Descrição

Lesion of brain Treated Stable status

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0221505
UMLS CUI [1,2]
C1522326
UMLS CUI [1,3]
C0205360
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
history of prior unstable angina, myocardial infarction, chf, uncontrolled ventricular arrhythmias within 12 months
Descrição

Angina, Unstable | Myocardial Infarction | Congestive heart failure | Ventricular arrhythmia Uncontrolled

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0002965
UMLS CUI [2]
C0027051
UMLS CUI [3]
C0018802
UMLS CUI [4,1]
C0085612
UMLS CUI [4,2]
C0205318
history of prior ≥ g 3 hypersensitivity (hsr) or any toxicity to trastuzumab or pertuzumab that warranted permanent cessation of this agent
Descrição

Hypersensitivity trastuzumab | Hypersensitivity pertuzumab | Toxicity trastuzumab | Toxicity pertuzumab

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0728747
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C1328025
UMLS CUI [3,1]
C0040539
UMLS CUI [3,2]
C0728747
UMLS CUI [4,1]
C0040539
UMLS CUI [4,2]
C1328025
≥ to g 2 peripheral neuropathy
Descrição

Peripheral Neuropathy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0031117
history of hepatitis b or c
Descrição

Hepatitis B | Hepatitis C

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0019163
UMLS CUI [2]
C0019196
pregnant patients
Descrição

Pregnancy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0032961
Voltar ao início da página

Similar models

Eligibility Metastatic HER2-Positive Breast Cancer NCT02252887

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
age ≥ to 18
boolean
C0001779 (UMLS CUI [1])
HER2-positive carcinoma of breast | Tumor Stage Classification
Item
stage iv her2 (+) breast cancer
boolean
C1960398 (UMLS CUI [1])
C0178759 (UMLS CUI [2])
HER2-positive carcinoma of breast | Immunohistochemistry | Fluorescent in Situ Hybridization | Primary tumor site | Site, metastatic cancer
Item
histologically documented her2 (+) breast cancer as defined as ihc 3+ or fish amplification of ≥ 2.0 of primary or metastatic site; results from the local lab are acceptable.
boolean
C1960398 (UMLS CUI [1])
C0021044 (UMLS CUI [2])
C0162789 (UMLS CUI [3])
C0475447 (UMLS CUI [4])
C0280457 (UMLS CUI [5])
ECOG performance status
Item
lecog performance status 0 -1
boolean
C1520224 (UMLS CUI [1])
Prior Therapy | trastuzumab | pertuzumab | Neoadjuvant Therapy | unresectable | Locally advanced breast cancer | metastatic
Item
prior treatment with trastuzumab + pertuzumab (hp)-based therapy or pertuzumab-based in the neoadjuvantadjuvant, unresectable, locally advanced, or metastatic setting.
boolean
C1514463 (UMLS CUI [1])
C0728747 (UMLS CUI [2])
C1328025 (UMLS CUI [3])
C0600558 (UMLS CUI [4])
C1519810 (UMLS CUI [5])
C3495949 (UMLS CUI [6])
C1522484 (UMLS CUI [7])
Prior Chemotherapy | metastatic | Anthracyclines | taxane | gemcitabine | trastuzumab | pertuzumab | lapatinib | neratinib | T-DM1 | Disease Progression
Item
≤ 3 prior chemotherapies in the metastatic setting. prior anthracycline, taxane, gemcitabine, and anti-her2 agents (i.e. trastuzumab, pertuzumab, lapatinib, neratinib, tdm-1, etc.) are allowed. if patients received prior gemcitabine, it could not have been combined with pertuzumab. patients should have progression of disease on current therapy.
boolean
C1514457 (UMLS CUI [1])
C1522484 (UMLS CUI [2])
C0282564 (UMLS CUI [3])
C0215136 (UMLS CUI [4])
C0045093 (UMLS CUI [5])
C0728747 (UMLS CUI [6])
C1328025 (UMLS CUI [7])
C1506770 (UMLS CUI [8])
C2713008 (UMLS CUI [9])
C2935436 (UMLS CUI [10])
C0242656 (UMLS CUI [11])
Measurable Disease
Item
measurable or non-measurable disease.
boolean
C1513041 (UMLS CUI [1])
LVEF
Item
lvef ≥ 50%
boolean
C0428772 (UMLS CUI [1])
Parameters Hematologic | White Blood Cell Count procedure | Absolute neutrophil count | Platelet Count measurement | Hemoglobin
Item
hematologic parameters: white blood cell (wbc) count of ≥ 3000/ul, absolute neutrophil count (anc) ≥ 1000/ul, platelets ≥ 100,000/ul, hemoglobin ≥10.0 g/dl
boolean
C0449381 (UMLS CUI [1,1])
C0205488 (UMLS CUI [1,2])
C0023508 (UMLS CUI [2])
C0948762 (UMLS CUI [3])
C0032181 (UMLS CUI [4])
C0019046 (UMLS CUI [5])
Parameters | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement
Item
non-hematologic parameters: bilirubin ≤ 1.5 mg/dl, ast/alt≤ 2.5 x upper limit of normal (uln), alkaline phosphatase ≤ 5 x uln.
boolean
C0449381 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C0201899 (UMLS CUI [3])
C0201836 (UMLS CUI [4])
C0201850 (UMLS CUI [5])
Creatinine measurement, serum
Item
creatinine ≤ 1.5 mg/dl
boolean
C0201976 (UMLS CUI [1])
Lesion of brain Treated Stable status
Item
patients with "treated and stable" brain lesions of a duration of ≥ 2 months may be enrolled.
boolean
C0221505 (UMLS CUI [1,1])
C1522326 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
Angina, Unstable | Myocardial Infarction | Congestive heart failure | Ventricular arrhythmia Uncontrolled
Item
history of prior unstable angina, myocardial infarction, chf, uncontrolled ventricular arrhythmias within 12 months
boolean
C0002965 (UMLS CUI [1])
C0027051 (UMLS CUI [2])
C0018802 (UMLS CUI [3])
C0085612 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
Hypersensitivity trastuzumab | Hypersensitivity pertuzumab | Toxicity trastuzumab | Toxicity pertuzumab
Item
history of prior ≥ g 3 hypersensitivity (hsr) or any toxicity to trastuzumab or pertuzumab that warranted permanent cessation of this agent
boolean
C0020517 (UMLS CUI [1,1])
C0728747 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1328025 (UMLS CUI [2,2])
C0040539 (UMLS CUI [3,1])
C0728747 (UMLS CUI [3,2])
C0040539 (UMLS CUI [4,1])
C1328025 (UMLS CUI [4,2])
Peripheral Neuropathy
Item
≥ to g 2 peripheral neuropathy
boolean
C0031117 (UMLS CUI [1])
Hepatitis B | Hepatitis C
Item
history of hepatitis b or c
boolean
C0019163 (UMLS CUI [1])
C0019196 (UMLS CUI [2])
Pregnancy
Item
pregnant patients
boolean
C0032961 (UMLS CUI [1])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial